vTv Therapeutics Inc. (NASDAQ:VTVT) Sees Large Increase in Short Interest

vTv Therapeutics Inc. (NASDAQ:VTVT) was the target of a large increase in short interest during the month of February. As of February 13th, there was short interest totaling 50,829 shares, an increase of 61.2% from the January 29th total of 31,525 shares. Based on an average daily trading volume, of 28,349 shares, the days-to-cover ratio is currently 1.8 days. Currently, 1.3% of the shares of the company are short sold. Currently, 1.3% of the shares of the company are short sold. Based on an average daily trading volume, of 28,349 shares, the days-to-cover ratio is currently 1.8 days.

Institutional Investors Weigh In On vTv Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. 683 Capital Management LLC bought a new stake in vTv Therapeutics during the 4th quarter valued at approximately $731,000. Goldman Sachs Group Inc. bought a new stake in shares of vTv Therapeutics during the fourth quarter valued at approximately $221,000. Geode Capital Management LLC lifted its holdings in shares of vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after buying an additional 12,896 shares in the last quarter. Finally, Baker BROS. Advisors LP boosted its position in shares of vTv Therapeutics by 52.4% during the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after acquiring an additional 51,000 shares during the last quarter. 17.51% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

VTVT has been the topic of a number of recent analyst reports. Wall Street Zen raised shares of vTv Therapeutics to a “sell” rating in a report on Saturday, December 27th. TD Cowen assumed coverage on shares of vTv Therapeutics in a research report on Monday, January 5th. They set a “buy” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of vTv Therapeutics in a research report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and set a $47.00 target price (up from $36.00) on shares of vTv Therapeutics in a research note on Friday, December 19th. Finally, BTIG Research reissued a “buy” rating and set a $49.00 price target (up from $40.00) on shares of vTv Therapeutics in a report on Tuesday, January 27th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $55.25.

vTv Therapeutics Trading Down 3.0%

Shares of NASDAQ VTVT opened at $38.16 on Friday. vTv Therapeutics has a 12-month low of $14.00 and a 12-month high of $44.00. The firm has a market capitalization of $150.35 million, a price-to-earnings ratio of -11.49 and a beta of 0.50. The firm has a 50 day moving average of $36.56 and a 200 day moving average of $28.02.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.